Is Immunome Inc (IMNM) overvalued? · rev $9.0M
Immunome Inc (IMNM) is a biotechnology company listed on US.
This page asks whether Immunome Inc (IMNM) looks expensive on cached numbers — not a short thesis.
Latest reported IMNM revenue for 2024-12-31 was $9.0M. Net income was -$293.0M. Revenue was down 35.5% from 2023-12-31 to 2024-12-31. IMNM currently screens at market cap $2.47B.
IMNM currently screens at market cap $2.47B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IMNM 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IMNM stock page for the full model, not this heading.
Not investment advice.